Dr. Sean E. Harper serves as Executive Vice President Research and Development of Amgen Inc., since February 2012. Dr. Harper joined the Company in 2002 and has held leadership roles in early development, medical sciences and global regulatory and safety
Executive Vice President - Research and Development
Age: 49 President Since 2012 Ph.D
|Harper served as Senior Vice President, Global Development and Corporationrationrate Chief Medical Officer from March 2007 to February 2012. Prior to joining the Company, Dr. Harper worked for five years at Merck Research Laboratories.|
The company has return on total asset (ROA) of 7.37 % which means that it generated profit of $7.37 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 23.95 % meaning that it created $23.95 on every $100 dollars invested by stockholders.
The company currently holds 23.89 B in liabilities with Debt to Equity (D/E) ratio of 1.23 which is about average as compared to similar companies. Amgen Inc has Current Ratio of 5.47 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.
Entity SummaryAmgen Inc., a biotechnology medicines company, engages in the discovery, development, manufacture, and marketing of human therapeutic solutions in the areas of supportive cancer care, inflammation, nephrology, and bone diseases primarily in the United States, Europe, and Canada. Amgen Inc [AMGN] is traded on NASDAQ in USA. It is located in Thousand Oaks, CA and employs 18,000 people. Filter other
|Click to run this filter|| |
Filter Other Insiders
| AMGN Nasdaq
Currency: USD - US Dollar
Traded on NASDAQ
Amgen Inc has less than 39.38 (%) percent chance of experiencing financial distress in the next 2 years of operations.
Amgen price boundaries
Promote Amgen and Sean Harper